Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 53 for Chronic lymphoid leukemia

Edit search filters
  1. A Study of Idelalisib Combined with BI 836826 for Patients with Chronic Lymphocytic Leukemia

    Rochester, MN

  2. A Study to Evaluate Daratumumab and Ibrutinib to Treat Relapsed / Refractory Chronic Lymphocytic Leukemia Treatment (DIRECT)

    Jacksonville, FL

  3. Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction

    Rochester, MN

  4. Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy

    Jacksonville, FL

  5. Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

    Jacksonville, FL

  7. Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

    Scottsdale/Phoenix, AZ, Rochester, MN

  8. A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared with Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

    Jacksonville, FL

  9. A Study to Evaluate the Safety and Tolerability of KTE-X19 in Adults with Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

    Scottsdale/Phoenix, AZ, Rochester, MN

  10. A Study of APG-2575 Alone or in Combination with Other Therapeutic Agents to Treat Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    Jacksonville, FL

.

Mayo Clinic Footer